- Conditions
- Presbyopia
- Interventions
- Pilocarpine Ophthalmic administered with the Optejet dispenser, Placebo administered with the Optejet dispenser
- Combination Product
- Lead sponsor
- Eyenovia Inc.
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- San Diego, California • Fairfield, Connecticut • Louisville, Kentucky + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 205
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more
- Conditions
- Nonallergic Irritant Rhinitis
- Interventions
- Capsaicin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stable Coronary Artery Disease, Percutaneous Coronary Intervention
- Interventions
- CMX-2043, Placebo control
- Drug
- Lead sponsor
- Ischemix, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Worcester, Massachusetts • Durham, North Carolina
- Conditions
- Anesthesia, Local
- Interventions
- AG-920, Placebo
- Drug
- Lead sponsor
- American Genomics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- McAllen, Texas
- Conditions
- Migraine, Facial Pain or Pressure, Headache
- Interventions
- Topical solution of 4% lidocaine, Saline 0.9%
- Drug
- Lead sponsor
- Association of Migraine Disorders
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution
- Drug
- Lead sponsor
- Mitotech, SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Dry Eye Disease
- Interventions
- Topical spironolactone ophthalmic solution, 0.005 mg/cc, Placebo
- Drug
- Lead sponsor
- Richard W Yee, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Bellaire, Texas
- Conditions
- Dry Eye Disease
- Interventions
- OK-101, Placebo
- Drug
- Lead sponsor
- Okyo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
- Conditions
- Nasal Allergies, Allergies
- Interventions
- AL-53817 nasal spray solution, Vehicle nasal spray
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Presbyopia
- Interventions
- Pilocarpine HCl, Vehicle
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Glendale, California • Inglewood, California + 19 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Capsaicin Topical Solution, Drug product vehicle
- Drug · Other
- Lead sponsor
- Propella Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Clearwater, Florida • Tampa, Florida • Dallas, Texas
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo)
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 12
- States / cities
- Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
- Conditions
- Macular Degeneration
- Interventions
- Microplasmin, Placebo control
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Atelectasis, Ventilation, Mechanical
- Interventions
- Pulmozyme (nebulized dornase alpha), Saline
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- OTX-TP, Timolol
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Preoperative Skin Preparation
- Interventions
- Chlorhexidine gluconate, N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride, Placebo
- Drug
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Butte, Montana
- Conditions
- Corneal Epithelial Disorders
- Interventions
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Drug
- Lead sponsor
- Senju Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Glendora, California • Lancaster, California + 16 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Postsurgical Pain
- Interventions
- Placebo Injection, AYX1 Injection 110 mg, AYX1 Injection 330 mg
- Drug
- Lead sponsor
- Adynxx, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 7
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Boynton Beach, Florida + 4 more
- Conditions
- Seborrheic Keratosis
- Interventions
- A-101 Vehicle, A-101 (40) Topical Solution, A-101 (32.5) Topical Solution
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 5
- States / cities
- Snellville, Georgia • Clinton Township, Michigan • Portland, Oregon + 2 more
- Conditions
- Knee Osteoarthritis
- Interventions
- PTP-01, Placebo control / saline vehicle
- Biological · Other
- Lead sponsor
- Doron Therapeutics Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • La Mesa, California • West Hills, California + 5 more
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Exendin-(9-39), placebo
- Drug
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania